Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of luspatercept in Japanese adults with lower-risk myelodysplastic syndromes and non-transfusion-dependent anemia
jRCT2080224675Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by Bristol Myers Squibb. Started May 2019; status: completed.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2080224675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224675.